IVT Fluocinolone XR (EC-104) / Eclipse Life Sciences - LARVOL DELTA

Eclipse reports positive phase 2 topline data on DME steroid implant (Eyes On Eyecare) - ""The BETTIS‑1 trial met its primary endpoint, demonstrating a favorable safety profile across both EC-104 formulations compared to OZURDEX, with low rates of treatment-related AEs and no unexpected safety signals...Moreover: At 24 weeks (and compared to OZURDEX), the secondary endpoints demonstrated superior clinically meaningful and durable improvement in both: Best-corrected visual acuity (BCVA); Optical coherence tomography (OCT) central subfield thickness (CST)...Eclipse Life Sciences plans to discuss phase 3 development of EC-104 with regulatory authorities, and is exploring partnership opportunities to accelerate phase 3 initiation and global commercialization to initiate a pivotal program in 2027...Plus: Full BETTIS-1 data will be presented at an unspecified upcoming ophthalmology conference and submitted for publication in a peer-reviewed journal."

New P3 trial • P2 data • Diabetic Macular Edema